48.4 VASOPRESSIN RECEPTOR ANTAGONISM AS A POTENTIAL TREATMENT OPTION FOR THE CORE SYMPTOMS OF ASD: RESULTS OF BALOVAPTAN FROM EARLY DEVELOPMENT
Volume: 58, Issue: 10, Pages: S373 - S373
Published: Oct 1, 2019
Abstract
The goal of this session is to describe the rationale for vasopressin 1a receptor (V1a) antagonism as a mechanism of action for the potential pharmacotherapy of core social and communication deficits in ASD. In addition, findings on the efficacy and safety of balovaptan, a selective V1a antagonist in early clinical development, will be...
Paper Details
Title
48.4 VASOPRESSIN RECEPTOR ANTAGONISM AS A POTENTIAL TREATMENT OPTION FOR THE CORE SYMPTOMS OF ASD: RESULTS OF BALOVAPTAN FROM EARLY DEVELOPMENT
Published Date
Oct 1, 2019
Volume
58
Issue
10
Pages
S373 - S373
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History